BNTX
BioNTech SE
$85.50
-2.93%
$21.5B
No data for this timeframe.
Vol
Market Cap$21.5B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (81%)
Inst. Holders7 funds
Inst. Value$1.1B
Inst. Activity2 buys / 0 sells
Insider Activity0B / 1S
Insider Net $-$5.5M
Reddit Sentiment47° Neutral
SEC Reports9
Press Releases7
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. 2M·CIK 0001776985·Prev Close $88.08
Recent Activity
Jun 8, 2026
SEC
BioNTech announced the commencement of its previously authorized $1.0 billion share buyback program, effective June 8, 2
6-K — Impact 4/10
Jun 1, 2026
clinical_trial_readout
Results Pending: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) (Phase 3) — Completed 31d ago
Trial: A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-C
Jun 1, 2026
SEC
BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) pl
6-K — Impact 6/10
May 22, 2026
SEC
BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, including new clinical data
6-K — Impact 4/10
May 12, 2026
Insider
Hanekamp Annemarie sold 12,586 shares
Chief Commercial Officer @ $0.00 ($0.00)
May 12, 2026
Insider
Hanekamp Annemarie sold 10,069 shares
Chief Commercial Officer @ $0.00 ($0.00)
May 12, 2026
Insider
Jimenez Kylie sold 10,488 shares
Chief People Officer @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — ADD
736,597 shares ($70.1M)
Price Targets
$122.99
+42.2% upside
Strong Buy
Current $86.50
Low $75.21
Median $128.30
High $156.27
19 analysts
$75.21
$156.27
Analyst Ratings
6Strong Buy
15Buy
5Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | UBS | UPGRADE | Neutral → Buy |
| May 22, 2026 | Bernstein | INITIATE | Market Perform |
| May 6, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-2.33 ▼ -1.5% | $-3.08 — $-1.72 | -46% YoY | 3 |
| Next Q | $0.66 ▼ -38.0% | $-0.02 — $1.24 | 647% YoY | 3 |
| Current FY | $-4.58 ▼ -4.9% | $-7.19 — $-3.30 | -854% YoY | 8 |
| Next FY | $-4.49 ▼ -12.7% | $-5.99 — $-3.18 | 2% YoY | 8 |
Latest Reports
NEUTRAL
6-K
4/10
BioNTech announced the commencement of its previously authorized $1.0 billion share buyback program, effective June 8, 2
Jun 8, 2026
BULLISH
6-K
6/10
BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xVEGF-A bispecific) pl
Jun 1, 2026
BULLISH
Press
7/10
BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in firs
May 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $564.9M | TRIM |
| DODGE & COX | $344.1M | DOUBLED |
| BANK OF AMERICA CORP | $70.1M | ADD |
| MORGAN STANLEY | $64.8M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $23.7M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | Hanekamp Annemarie | A | $0.00 |
| May 12, 2026 | Hanekamp Annemarie | A | $0.00 |
| May 12, 2026 | Jimenez Kylie | A | $0.00 |
| May 12, 2026 | Jimenez Kylie | A | $0.00 |
| May 12, 2026 | Poetting Sierk | A | $0.00 |
Reddit Sentiment
47°▼
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $1.1B total value (11,328,356 shares) as of 2025-Q4. Top holders: FMR, DODGE, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 5,933,594 | $564.9M | 52.4% | TRIM -33.2% |
| 2 | DODGE & COX | 3,614,491 | $344.1M | 31.9% | DOUBLED +315.7% |
| 3 | BANK OF AMERICA CORP /DE/ | 736,597 | $70.1M | 6.5% | ADD +28.5% |
| 4 | MORGAN STANLEY | 680,669 | $64.8M | 6.0% | TRIM -41.1% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 249,045 | $23.7M | 2.2% | ADD +30.0% |
| 6 | TWO SIGMA INVESTMENTS, LP | 108,258 | $10.3M | 1.0% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 5,702 | $542.9K | 0.1% | TRIM -57.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 573,356 | 736,597 | +28.5% | $70.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 108,258 | — | $10.3M | 2025-Q4 |
| FMR LLC | TRIM | 8,159,011 | 5,453,480 | -33.2% | $537.8M | 2025-Q3 |
| DODGE & COX | DOUBLED | 877,437 | 3,647,091 | +315.7% | $359.7M | 2025-Q3 |
| UBS Group AG | ADD | 451,488 | 770,640 | +70.7% | $76.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 129,024 | 573,356 | +344.4% | $56.5M | 2025-Q3 |
| DODGE & COX | NEW | — | 877,437 | — | $93.4M | 2025-Q2 |
| UBS Group AG | TRIM | 685,431 | 451,488 | -34.1% | $48.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 293,776 | 129,024 | -56.1% | $13.7M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 19,317 | 8,184 | -57.6% | $871.4K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 187,355 | 243,468 | +30.0% | $22.2M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 108,840 | 19,317 | -82.3% | $1.8M | 2025-Q1 |
| UBS Group AG | DOUBLED | 381,781 | 807,553 | +111.5% | $92.0M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 134,036 | 187,355 | +39.8% | $21.3M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 1,147,797 | 675,916 | -41.1% | $80.3M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 134,036 | — | $15.9M | 2024-Q3 |
4 unique insiders with 1 transactions. Net insider value: -$5.5M ($0.00 bought, $5.5M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | Hanekamp Annemarie | Chief Commercial Officer | A | 12,586 | $0.00 | $0.00 |
| May 12, 2026 | Hanekamp Annemarie | Chief Commercial Officer | A | 10,069 | $0.00 | $0.00 |
| May 12, 2026 | Jimenez Kylie | Chief People Officer | A | 10,488 | $0.00 | $0.00 |
| May 12, 2026 | Jimenez Kylie | Chief People Officer | A | 8,391 | $0.00 | $0.00 |
| May 12, 2026 | Poetting Sierk | Chief Operating Officer | A | 12,586 | $0.00 | $0.00 |
| May 12, 2026 | Poetting Sierk | Chief Operating Officer | A | 10,069 | $0.00 | $0.00 |
| May 12, 2026 | Zapata Gomez Ramon | Chief Financial Officer | A | 18,879 | $0.00 | $0.00 |
| May 12, 2026 | Zapata Gomez Ramon | Chief Financial Officer | A | 15,103 | $0.00 | $0.00 |
| Apr 22, 2026 | Poetting Sierk | Chief Operating Officer | SELL | 50,000 | $110.56 | $5.5M |
9 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 2 mixed, 4 neutral. Avg impact: 5.4/10.
NEUTRAL
6-K
4/10
BioNTech announced the commencement of its previously authorized $1.0 billion share buyback program,
Jun 8, 2026
BULLISH
6-K
6/10
BioNTech and BMS announced interim Phase 2 data from the ROSETTA Lung-02 trial of pumitamig (PD-L1xV
Jun 1, 2026
NEUTRAL
6-K
4/10
BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, includin
May 22, 2026
NEUTRAL
6-K
4/10
BioNTech held its 2026 Annual General Meeting, where all agenda items were approved by shareholders,
May 15, 2026
NEUTRAL
6-K
4/10
BioNTech announced a new $1.0 billion ADS repurchase program authorized through May 6, 2027, to be f
May 7, 2026
BEARISH
6-K
7/10
BioNTech reported Q1 2026 results with total revenue of €118.1M, down 35% YoY from €182.8M, driven b
May 5, 2026
MIXED
6-K
6/10
BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY from €182.8M) and a net loss of €531.9M (
May 5, 2026
MIXED
PRESS-RELEASE
6/10
BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted
May 5, 2026
BULLISH
6-K
8/10
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing endometria
Apr 13, 2026
BULLISH
7/10
BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus
May 30, 2026
NEUTRAL
5/10
BioNTech announced new clinical data for pumitamig (Phase 2/3 ROSETTA Lung-02 in 1L NSCLC) and gotis
May 22, 2026
NEUTRAL
3/10
BioNTech announced it will release its first-quarter 2026 financial results on May 5, 2026, followed
Apr 21, 2026
BULLISH
8/10
BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in advanced endometrial cance
Apr 11, 2026
BULLISH
8/10
BioNTech presented new clinical data from its late-stage lung cancer programs at the European Lung C
Mar 24, 2026
BEARISH
7/10
BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3% YoY, but posted a net loss of €1
Mar 10, 2026
MIXED
7/10
BioNTech announced that its co-founders, Ugur Sahin and Özlem Türeci, will establish an independent
Mar 10, 2026
Current analyst consensus: Strong Buy (81% buy). Based on 26 analysts: 6 strong buy, 15 buy, 5 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$122.99 mean target
+42.2% upside
Strong Buy (1.58)
$75.21 Low
$156.27 High
| Metric | Value |
|---|---|
| Current Price | $86.50 |
| Target Low | $75.21 |
| Target Mean | $122.99 |
| Target Median | $128.30 |
| Target High | $156.27 |
| # Analysts | 19 |
| Recommendation | Strong Buy (1.58) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-2.33 | $-3.08 | $-1.72 | -45.5% | -1.5% | 0↑ 1↓ | $0.2B | -40.3% | 3 |
| Next Q 2026-09-30 |
$0.66 | $-0.02 | $1.24 | 647.5% | -38.0% | 0↑ 1↓ | $1.2B | -23.2% | 3 |
| Current FY 2026-12-31 |
$-4.58 | $-7.19 | $-3.30 | -854.3% | -4.9% | 3↑ 2↓ | $2.1B | -25.4% | 8 |
| Next FY 2027-12-31 |
$-4.49 | $-5.99 | $-3.18 | 2.0% | -12.7% | 3↑ 2↓ | $2.2B | 2.6% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-2.328 | |
| 7d ago | $-2.402 | +0.074 |
| 30d ago | $-2.293 | -0.035 |
| 60d ago | $-1.511 | -0.817 |
| 90d ago | $-1.703 | -0.625 |
11 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | UBS | UPGRADE | Neutral | Buy |
| May 22, 2026 | Bernstein | INITIATE | — | Market Perform |
| May 6, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 11, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | TD Cowen | MAINTAIN | Hold | Hold |
| Mar 11, 2026 | BMO Capital | MAINTAIN | Outperform | Outperform |
| Mar 10, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | Goldman Sachs | UPGRADE | Neutral | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 15 | 5 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 15 | 5 | 0 | 0 | 81% | |
| Apr 1, 2026 | 6 | 15 | 6 | 0 | 0 | 78% | |
| Mar 1, 2026 | 7 | 16 | 5 | 0 | 0 | 82% | |
| Feb 1, 2026 | 7 | 17 | 4 | 0 | 0 | 86% | |
| Jan 1, 2026 | 7 | 15 | 5 | 0 | 0 | 81% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
47°
Neutral
Bearish
Neutral
Bullish
11 mentions
2 bullish
3 bearish
8 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 31, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 31, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 18, 2026 | 2 | 50° Neutral | 1 | 1 | 2 |
| May 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 21, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 21, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 21, 2026 | 3 | 44° Neutral | 0 | 0 | 3 |
| Apr 21, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
BNTX ASCO 2026 DD
▲ 1
💬 0
⚡ 0.5
$BNTX ASCO 2026 conference
▲ 1
💬 1
⚡ 0.5
Jun 2, 2026
Clinical Trial
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
Phase Phase 3 — COMPLETED
Jun 1, 2026
clinical_trial_readout
Results Pending: BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) (Phase 3) — Completed 31d ago
Trial: A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Cons
May 30, 2026
announcement
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
BioNTech and BMS' PD-L1xVEGF-A bispecific pumitamig shows encouraging efficacy in patients with non-small cell lung cancer in ROSETTA Lung-02 trial
May 29, 2026
Clinical Trial
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
Phase Phase 3 — COMPLETED
May 22, 2026
announcement
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
BioNTech SE will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at ASCO 2026.
May 15, 2026
announcement
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
BioNtech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today.
May 8, 2026
Clinical Trial
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
Phase Phase 2 — TERMINATED
May 7, 2026
announcement
BioNTech Announces New ADS Repurchase Program
BioNTech SE today announced that it has authorized a new share repurchase program under which the Company may repurchase American Depositary Shares.
May 5, 2026
earnings
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
BioNTech SE (Nasdaq: BNTX) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress
May 5, 2026
earnings_calendar
BNTX Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
Clinical Trial
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 4, 2026
Clinical Trial
A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: BNT162b2 (2025/2026 formulation) (Phase 3)
Trial: A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: BNT162b2 Vaccine (Phase 3)
Trial: A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
Sponsor: BioNTech SE
Phase: Phase 3 | Status: ACTIVE_NOT
May 2, 2026
clinical_trial_readout
T-90d Trial Readout: BNT162b2 Vaccine (Phase 3)
Trial: A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
Sponsor: BioNTech SE
Phase: Phase 3 | Status: ACTIVE_NOT
May 2, 2026
clinical_trial_readout
T-90d Trial Readout: BNT162b2 (2025/2026 formulation) (Phase 3)
Trial: A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher
Apr 27, 2026
clinical_trial_readout
T-90d Trial Readout: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose (Phase 3)
Trial: A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Sponsor: BioNTech SE
Phase: Phase 3 | Status: ACTI
Apr 24, 2026
clinical_trial_readout
T-90d Trial Readout: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose (Phase 3)
Trial: A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Sponsor: BioNTech SE
Phase: Phase 3 | Status: ACTI
Apr 22, 2026
short_interest
FTD: BNTX — 51,361 shares ($5.7M) failed to deliver
Settlement: 20260422, Price: $111.60, FTD Value: $5,731,887.6, BIONTECH SE ADS (DEU)
Apr 21, 2026
announcement
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
<p align="justify"><b>MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE)</b> -- <a href="https://www.globenewswire.com/Tracker?data=gPegM69roQA28YCPs8cYo